The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers.

ABSTRACT:

Background

BRAF mutations are classified into four molecularly distinct groups, and Class 1 (V600) mutant tumors are treated with targeted therapies. Effective treatment has not been established for Class 2/3 or BRAF Fusions. We investigated whether BRAF mutation class differed according to clinical, genomic, and transcriptomic variables in cancer patients.

Methods

Using the AACR GENIE (v.12) cancer database, the distribution of BRAF mutation class in adult cancer patients was analyzed according to sex, age, primary race, and tumor type. Genomic alteration data and transcriptomic analysis was performed using The Cancer Genome Atlas.

Results

BRAF mutations were identified in 9515 (6.2%) samples among 153,834, with melanoma (31%), CRC (20.7%), and NSCLC (13.9%) being th

SUBMITTER: Kazandjian S 

PROVIDER: S-EPMC10814895 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature